AJANTPHARM2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2020-04-01 2021-03-31 2020-07-20 INR Crores First quarter Single segment PHARMACEUTICAL 2020-04-01 2020-06-30 Unaudited Standalone 5608500000.00 131000000.00 5739500000.00 1533200000.00 225900000.00 -255300000.00 1238200000.00 12000000.00 268600000.00 1132200000.00 4154800000.00 1584700000.00 0.00 1584700000.00 380700000.00 47100000.00 427800000.00 0.00 1156900000.00 0.00 0.00 0.00 0.00 1156900000.00 -6400000.00 1150500000.00 1150500000.00 0.00 175400000.00 2 13.26 13.26 0.00 0.00 13.26 13.26 1. The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2020. n2. Statutory Auditors have expressed an unqualified review opinion for quarter ended 30 June 2020. n4. The Company has taken into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Company has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The Company will continue to closely monitor future economic conditions to ensure business continuity. n5. Exceptional item in 31 March 2020 quarter and year end 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. In addition to the claim that has been settled, the Company has received Rs. 16 crores against the pending claims. The survey is in progress and accordingly no further amounts claimed have been recognised pending the conclusion of the survey. n6. During the quarter Nil equity shares (previous quarter 1,000) of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ` Nil (previous quarter Rs. 2,000) and securities premium account by ` Nil crores (previous quarter Rs. 0.12 crores). n7. The figures for the quarter ended 31 March 2020 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter ended 31 December 2019. n8. The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . n9. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. Other Expenses 1132200000.00